BIOMARKER WORLD CONGRESS 2009

Make plans to join over 400 of your colleagues...Register today!

The signature event in Cambridge Healthtech Institute’s Biomarker Series, The Biomarker World Congress 2009 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for decision makers. Now in its fifth year, the Biomarker World Congress is the leading annual meeting dedicated to biomarker research and implementation that consistently delivers a cutting-edge agenda, 400+ senior delegates, and a sold-out exhibit hall.

Coverage Includes:

• Clinical applications of biomarkers
• Biomarkers in translational medicine
• Implementing personalized medicine
• Pharmacogenomics and companion diagnostics
• Biomarker assay development and validation
• Clinical validation of biomarkers
• Biomarkers for safety assessment and clinical pharmacology
• Biomarkers for patient selection and monitoring response to therapy
• Biomarker discovery strategies
• Biomarkers for molecular diagnostics
• Disease-specific biomarkers
• Biomarkers for go/no-go decisions
• Regulatory issues

Featured Speakers Klaus Lindpaintner Head, Medical Genomics; VP, Research, Roche Giora Feuerstein AVP & Head Discovery, Translational edicine, Wyeth Nicholas C. Dracopoli VP, Biomarkers Centocor, Johnson & Johnson David Wholley, Director, Biomarkers Consortium, Foundation for the NIH Lawrence J. Lesko Director, Clinical Pharmacology CDER, FDA C. Thomas Caskey EVP, Molecular Medicine and Genetics, Univ. of Texas Health Science Center Geert Kolvenbag Global Product VP, Oncology, AstraZeneca Francois Legay Global Head, Marker Assays, Novartis Robert S. Epstein SVP & Chief Medical Officer, Medco Health Solutions Phil Hewitt Head, Molecular Toxicology, Merck